Compare NVDA & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVDA | MRK |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6T | 268.7B |
| IPO Year | 1999 | N/A |
| Metric | NVDA | MRK |
|---|---|---|
| Price | $182.05 | $121.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 39 | 13 |
| Target Price | ★ $255.82 | $121.00 |
| AVG Volume (30 Days) | ★ 175.3M | 14.1M |
| Earning Date | 02-25-2026 | 02-03-2026 |
| Dividend Yield | 0.02% | ★ 2.80% |
| EPS Growth | ★ 59.73 | 8.01 |
| EPS | 4.04 | ★ 7.28 |
| Revenue | ★ $187,142,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | $66.48 | $5.02 |
| Revenue Next Year | $54.24 | $5.31 |
| P/E Ratio | $45.25 | ★ $16.68 |
| Revenue Growth | ★ 65.22 | 1.31 |
| 52 Week Low | $86.62 | $73.31 |
| 52 Week High | $212.19 | $123.33 |
| Indicator | NVDA | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 71.39 |
| Support Level | $171.31 | $116.10 |
| Resistance Level | $193.61 | $122.46 |
| Average True Range (ATR) | 6.75 | 3.23 |
| MACD | 0.19 | 0.58 |
| Stochastic Oscillator | 47.57 | 97.40 |
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence to run large language models. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).